A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) NCT04222972 RET-fusion Non ...
Lung Neoplasm
Carcinoma, Non-...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Disea...
Head and Neck N...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Germ...
Neoplasms, Nerv...
Pralsetinib
Carboplatin
Cisplatin
Pemetrexed
Pembrolizumab
Gemcitabine
Paclitaxel
Nab-Paclitaxel
18 Years - Hoffmann-La Roche View A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC NCT03134872 Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Thoracic Neopla...
Lung Diseases
Respiratory Tra...
Neoplasms by Si...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
Carboplatin
Pemetrexed
18 Years - 70 Years Jiangsu HengRui Medicine Co., Ltd. View A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116 Locally Advance...
Metastatic Soli...
Oral repotrecti...
12 Years - Turning Point Therapeutics, Inc. View A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC NCT03085069 Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Lung Disease
Respiratory Tra...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
18 Years - 80 Years Jiangsu HengRui Medicine Co., Ltd. View A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC NCT03134872 Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Thoracic Neopla...
Lung Diseases
Respiratory Tra...
Neoplasms by Si...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
Carboplatin
Pemetrexed
18 Years - 70 Years Jiangsu HengRui Medicine Co., Ltd. View A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC NCT03085069 Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Lung Disease
Respiratory Tra...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
18 Years - 80 Years Jiangsu HengRui Medicine Co., Ltd. View (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Nerv...
EGFR T790M
EGFR C797S
EGFR L858R
EGFR Gene Mutat...
EGF-R Positive ...
EGFR Exon 19 De...
EGFR Mutation R...
EGFR Activating...
Protein Kinase ...
Antineoplastic ...
Thoracic Neopla...
BLU-945
osimertinib
18 Years - Blueprint Medicines Corporation View A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116 Locally Advance...
Metastatic Soli...
Oral repotrecti...
12 Years - Turning Point Therapeutics, Inc. View Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors NCT03037385 RET-altered Non...
Medullary Thyro...
RET-altered Pap...
RET-altered Col...
RET-altered Sol...
Lung Neoplasm
Carcinoma, Non-...
Thyroid Disease...
Thyroid Neoplas...
Thyroid Cancer,...
Carcinoma, Neur...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Endocrine Syste...
Endocrine Gland...
Head and Neck N...
Adenocarcinoma,...
Adenocarcinoma
Carcinoma
Neoplasms, Glan...
Neoplasms by Hi...
Neuroendocrine ...
Neuroectodermal...
Neoplasms, Germ...
Neoplasms, Nerv...
Colonic Neoplas...
Colorectal Neop...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
pralsetinib (BL...
18 Years - Hoffmann-La Roche View (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 Lung Neoplasm M...
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
EGFR Exon 20 Mu...
EGFR Exon 20 In...
EGFR Activating...
Antineoplastic ...
Metastatic Lung...
Brain Metastase...
EGFR-mutated NS...
EGFR Atypical M...
BLU-451
Carboplatin
Pemetrexed
18 Years - Blueprint Medicines Corporation View A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC NCT03085069 Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Lung Disease
Respiratory Tra...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
18 Years - 80 Years Jiangsu HengRui Medicine Co., Ltd. View (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Nerv...
EGFR T790M
EGFR C797S
EGFR L858R
EGFR Gene Mutat...
EGF-R Positive ...
EGFR Exon 19 De...
EGFR Mutation R...
EGFR Activating...
Protein Kinase ...
Antineoplastic ...
Thoracic Neopla...
BLU-945
osimertinib
18 Years - Blueprint Medicines Corporation View